Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

Frontiers in Immunology

Immunology

Ruimin Wang¹  Jiajin Liu¹  Baixuan Xu¹  Xiaodan Xu¹  Guangyu Ma¹  Jinming Zhang¹  Xiaohui Luan²  Guanyun Wang³  Zhanbo Wang⁴  Wenwen Zhang⁵  Shichun Lu⁵ 

[1] Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China;Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China;Graduate School, Medical School of Chinese People’s Liberation Army (PLA), Beijing, China;Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China;Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China;Department of Pathology, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China;Faculty of Hepato-Pancreato-Biliary Surgery, Chinese People’s Liberation Army (PLA) General Hospital/Institute of Hepatobiliary Surgery of Chinese People’s Liberation Army/Key Laboratory of Digital Hepetobiliary Surgery, People’s Liberation Army, Beijing, China;

关键词: unresectable hepatocellular carcinoma;    conversion therapy;    major pathological response;    prognosis;    F-FDG PET;   

DOI  :  10.3389/fimmu.2023.1219757

 received in 2023-05-09, accepted in 2023-05-12,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Wang, Zhang, Luan, Wang, Liu, Xu, Zhang, Xu, Lu, Wang and Ma